CD28 and gram-negative bacterial infections: The first-generation mimetic peptide p2TA, derived from the CD28 homodimer interface (Figure 2), proved effective as an antagonist of CD28 signaling not only against superantigen toxicity but also against Gram-positive as well as Gram-negative bacterial infections and polymicrobial sepsis, with a clear therapeutic benefit.